Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or BRAF

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

(2018) Yan Wang et al.   BMC CANCER

KRAS: Reasons for optimism in lung cancer

(2018) C.R. Lindsay et al.   EUROPEAN JOURNAL OF CANCER

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

(2018) Jessica J. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer

(2018) Shaodong Hong et al.   JAMA Oncology

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

(2018) A Kron et al.   ANNALS OF ONCOLOGY

Successful treatment of a NSCLC patient harbouring an EGFR mutation and a concomitant Met Exon 14 skipping mutation combining afatinib and crizotinib

(2018) Diego Kauffmann-Guerrero et al.   Clinical Lung Cancer

Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures

(2018) Huiyan Deng et al.   PATHOLOGY RESEARCH AND PRACTICE

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

(2018) Youjin Kim et al.   Journal of Thoracic Oncology

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

(2017) E-E Ke et al.   Journal of Thoracic Oncology

Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

(2017) Sabine Schmid et al.   Journal of Thoracic Oncology

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France

(2017) Nicolas Guibert et al.   Journal of Thoracic Oncology

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer

(2017) Marcel Wiesweg et al.   Journal of Thoracic Oncology

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma

(2017) You-cai Zhu et al.   Thoracic Cancer

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review

(2017) You-cai Zhu et al.   Thoracic Cancer

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).

(2017) M. G. Kris et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China

(2016) Xuefei Li et al.   BMC CANCER

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy

(2016) Paola Ulivi et al.   Clinical Lung Cancer

EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect

(2016) Nora Sahnane et al.   Clinical Lung Cancer

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

(2016) Tatsuya Yoshida et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis

(2016) Chenyang Ye et al.   OncoTargets and Therapy

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

(2015) Weijing Cai et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas

(2015) Juliana Eng et al.   Journal of Thoracic Oncology

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor

(2014) J. K. Won et al.   ANNALS OF ONCOLOGY

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History

(2014) A. Karlsson et al.   CLINICAL CANCER RESEARCH

Lung Cancers with ConcomitantEGFRMutations andALKRearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

(2014) Jin-Ji Yang et al.   CLINICAL CANCER RESEARCH

Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of the literature with demonstration of genes alteration into the same tumor cells

(2014) Licia Baldi et al.   LUNG CANCER

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations

(2013) T. Kinno et al.   ANNALS OF ONCOLOGY

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE